Carcinoma in situ of scrotum
ICD-10 D07.61 is a billable code used to indicate a diagnosis of carcinoma in situ of scrotum.
Carcinoma in situ of the scrotum refers to a localized form of cancer that is confined to the scrotal tissue without invasion into surrounding structures. This condition is characterized by abnormal cells that have the potential to develop into invasive cancer if left untreated. The most common type of carcinoma in situ found in the scrotum is squamous cell carcinoma, often associated with chronic irritation or inflammation, such as from poor hygiene or exposure to carcinogenic substances. Diagnosis typically involves a biopsy of the affected area, and treatment options may include surgical excision, topical chemotherapy, or photodynamic therapy. Surveillance protocols are critical for monitoring progression, as the risk of developing invasive cancer increases over time. Regular follow-up examinations and imaging studies may be recommended to ensure early detection of any changes in the scrotal tissue. The prognosis is generally favorable with appropriate management, but vigilance is necessary due to the potential for progression to invasive disease.
Detailed documentation of clinical findings, biopsy results, and treatment plans.
Diagnosis and management of scrotal lesions, follow-up after treatment.
Ensure accurate coding of any associated conditions or complications.
Comprehensive skin examination notes, including descriptions of lesions and biopsy details.
Management of skin cancers, including in situ lesions.
Document any prior treatments or interventions that may affect coding.
Used when excising a carcinoma in situ of the scrotum.
Document the size of the lesion and the margins of excision.
Urologists and dermatologists should ensure accurate coding based on the excised diameter.
Carcinoma in situ of the scrotum is significant as it indicates the presence of abnormal cells that have not invaded surrounding tissues. Early detection and treatment are crucial to prevent progression to invasive cancer.
